Rockwell Medical Says Phase 3 CRUISE Data Accepted as Late-Breaking Trial Abstract
October 02, 2013 at 08:05 AM EDT
Rockwell Medical, Inc. (NASDAQ: RMTI ), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that the Phase 3 CRUISE-1 and CRUISE-2 clinical abstract submitted as a Late-Breaking Clinical Trial (LBCT) to the ASN
